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Abstract  68 
While progress has been made in characterizing humoral immunity to Zika virus 69 
(ZIKV) in humans, little is known regarding the corresponding T cell responses to 70 
ZIKV. Here we investigate the kinetics and viral epitopes targeted by T cells 71 
responding to ZIKV and address the critical question of whether pre-existing dengue 72 
virus (DENV) T cell immunity modulates these responses. We find that memory T 73 
cell responses elicited by prior infection with DENV or vaccination with Tetravalent 74 
Dengue Attenuated Vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-75 
reactivity is explained by the sequence similarity of the two viruses, as the ZIKV 76 
peptides recognized by DENV-elicited memory T cells are identical or highly 77 
conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences 78 
the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute 79 
phase of infection are detected earlier and in greater magnitude in DENV-immune 80 
patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the 81 
convalescent phase in DENV-naive donors, but declines in DENV pre-exposed 82 
donors, compatible with more efficient control of ZIKV replication and/or clearance 83 
of ZIKV antigen. The quality of responses is also influenced by previous DENV 84 
exposure, and ZIKV-specific CD8 T cells form DENV pre-exposed donors selectively 85 
up-regulated granzyme B and PD1, as compared to DENV-naïve donors. Finally, we 86 
discovered that ZIKV structural proteins (E, prM and C) are major targets of both the 87 
CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in 88 
nonstructural proteins.  89 
 90 
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Importance 91 
The issue of potential ZIKV and DENV cross-reactivity  and how  pre-existing DENV 92 
T cell immunity modulates ZIKA T cell responses is of great relevance as the two 93 
viruses often co-circulate and ZIKA virus has been spreading in geographical regions 94 
where DENV is endemic or hyper-endemic. Our data show that memory T cell 95 
responses elicited by prior infection with DENV recognize ZIKV-derived peptides 96 
and that DENV exposure prior to ZIKV infection influences the timing, magnitude 97 
and quality of the T cell response. Additionally we show that ZIKV-specific 98 
responses target different proteins than DENV-specific responses, pointing towards 99 
important implications for vaccine design against this global threat. 100 
 101 
  102 
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Introduction 103 
The pandemic rise of Zika virus (ZIKV) has recently commanded the attention of the 104 
general public and medical research community alike  105 
(13, 15, 31, 33).  106 
ZIKV is a flavivirus most closely related to dengue virus (DENV)(24, 53) but also 107 
related with Japanese encephalitis virus (JEV), West Nile virus (WNV), and yellow 108 
fever virus (YF), all of which are transmitted primarily by mosquitoes (54). . 109 
Understanding host protective immunity to this virus is critical for the design of 110 
optimal vaccines, but little is currently known about the immune responses to ZIKV 111 
in humans since infections with ZIKV have not been frequent in the past (27, 29). 112 
This is in contrast to a substantial wealth of information related to T cell immunity 113 
against the closely related DENV(44, 45, 49). 114 
 115 
In the case of DENV, CD8 T cell responses target mostly non-structural (NS) proteins 116 
such as NS3, NS4B and NS5, while CD4 T cell responses are focused on the C, E and 117 
NS5 proteins, even though serotype specific differences have been noted (1, 2, 43, 118 
44, 46). The main protein targets of CD4 and CD8 T cell immunity are presently 119 
unknown for ZIKV. This dearth of information is a severe knowledge gap as robust T 120 
cell responses may be required for optimal ZIKV vaccine efficacy (29).  121 
 122 
The issue of potential ZIKV and DENV cross-reactivity is of relevance for 123 
development of both diagnostic tests and vaccines. ZIKV and DENV have significant 124 
sequence similarity, share the same arthropod host and the geographic range of 125 
 o
n
 August 13, 2019 at University of Liverpool Library
http://jvi.asm.org/
D
ow
nloaded from
 
 7 
ZIKV overlaps largely with areas where DENV is endemic or hyper-endemic (53) 126 
(52). The concomitant co-circulation of DENV and ZIKV represents yet another 127 
biomedical challenge since this phenomenon of common dual exposure increases 128 
the potential for cross-reaction. Serological cross-reactivity has been addressed by 129 
several reports (5, 9, 20, 28, 36, 37). However, it is currently unknown as to what 130 
extent ZIKV and DENV may cross-react with each other at the level of T cell 131 
immunity.  132 
 133 
According to the well established phenomenon of heterologous immunity(32, 50), It 134 
is possible that pre-existing DENV immunity will affect T cell responses to ZIKV and 135 
hence influence the dynamics and severity of ZIKV epidemics. Importantly, previous 136 
DENV infection can in some instances increase severity of a second DENV infection 137 
with a heterologous serotype, likely through antibody dependent enhancement 138 
(ADE) of infection and disease (30). In the Phase IIb/III clinical trials of the first 139 
licensed tetravalent dengue vaccine, increased vaccine efficacy in DENV pre-140 
exposed as opposed to DENV-naive vaccinees was observed, suggesting a possible 141 
protective role of pre-existing cross-reactive DENV-specific T cells that are boosted 142 
upon vaccination (29). Thus, it is also possible that pre-exposure to either ZIKV or 143 
DENV infection will influence the disease course following infection with the other 144 
virus in either a favorable or detrimental fashion. For all these reasons, it is 145 
necessary to gain insight into human T cell responses to ZIKV.  146 
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Material and Methods  147 
 148 
Human blood samples  149 
All samples have been collected after informed consent and the study has 150 
been approved by the LJI IRB committee (IRB#: VD-154). An overview of the clinical 151 
and serological characteristics of all ZIKA samples is provided in Table 1. The 152 
sample allocation was provided by collaborators that collected the samples. The 153 
investigators were aware of the group allocation during the experiment and when 154 
assessing the outcome. In addition Supplementary Table 1 provides a summary of 155 
the HLA typing data of the PBMC donor and DENV infection history were available 156 
of all the donors analyzed in this study. 157 
 158 
Samples from flavivirus naive controls 159 
Healthy adult male and non-pregnant female volunteers 18–50 years of age were 160 
enrolled from Baltimore, Maryland, Washington, DC, and Burlington, Vermont and 161 
tested for the presence of serum antibodies to all DENV serotypes, yellow fever 162 
virus, West Nile virus, and St. Louis encephalitis virus, as previously described (11).  163 
 164 
Samples from DENV endemic areas 165 
Blood donations from healthy adult blood donors of both sexes between the age of 166 
18 and 65 were collected by the National Blood Center, Ministry of Health, Colombo, 167 
Sri Lanka collected in anonymous fashion between the years of 2010 and 2016 and 168 
processed at the Genetech Research Institute as previously described(45). Similarly, 169 
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National Blood Center (NBC) of the Nicaraguan Red Cross in Managua, Nicaragua 170 
has provided anonymous blood samples collected between 2010 and 2014 prior to 171 
the introduction of ZIKV to the country(46).  172 
 173 
Samples from DENV tetravalent vaccination. 174 
Healthy donors were enrolled and vaccinated with TV005, a tetravalent DENV 175 
vaccine formulation. Blood samples were collected as a part of a phase I clinical 176 
trials (registration numbers NCT01506570 and NCT01436422) at the Johns 177 
Hopkins Bloomberg School of Public Health (JHSPH) and at the University of 178 
Vermont (UVM) Vaccine Testing Center and the Center for Immunization as 179 
previously reported(3, 17, 43).  180 
 181 
Samples from ZIKV virus endemic areas 182 
Blood samples were collected from patients displaying symptoms of a suspected 183 
ZIKV infection in Brazil, Nicaragua and Mexico. Samples were also collected from 184 
blood donors identified through routine donor screening in Puerto Rico and Florida.  185 
Infection with ZIKV was confirmed using RT-PCR as described in more detail below. 186 
All samples were screened for previous DENV exposure by measuring DENV-187 
specific IgG titers and/or neutralizing antibodies or from documented history of 188 
DENV infection. Depending on the time of sample collection after onset of 189 
symptoms, samples were either classified as acute (2-14 days post onset of 190 
symptoms or hospitalization) or convalescent (more than 15 days post onset of 191 
symptoms). Blood samples collected within the Recipient Epidemiology and Donor 192 
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Evaluation Study-III (REDSIII) were collected approximately 3 months following 193 
ZIKV RNA pos. blood donation. 194 
 195 
Samples from the Nicaraguan Pediatric Dengue Cohort Study (PDCS)  196 
A total of 14 children RT-PCR-pos. for ZIKV who experienced signs and symptoms of 197 
Zika, from the Nicaraguan Pediatric Dengue Cohort Study (PDCS) were included.  198 
The PDCS is a community-based prospective study of children 2 to 14 years of age 199 
that has been ongoing since August 2004 in Managua, Nicaragua (19). Participants 200 
present at the first sign of illness to the Health Center Sócrates Flores Vivas and are 201 
followed daily during the acute phase of illness. Acute and convalescent (~14-21 202 
days after onset of symptoms) blood samples are drawn for dengue, chikungunya 203 
and Zika diagnostic testing from patients meeting the case definition for dengue or 204 
Zika (starting in January 2016) or presenting with undifferentiated febrile illness. In 205 
the PDCS, a healthy blood sample is collected annually from participants; anti-DENV 206 
antibody titers are measured in paired annual samples using an Inhibition ELISA 207 
(EI)(4, 14), and infections are defined by seroconversion or a ≥4-fold rise in anti-208 
DENV titers. In this study, confirmed ZIKV cases were classified as DENV-naïve if 209 
they entered the cohort study with no detectable anti-DENV antibodies (as 210 
measured by EI) and had no documented DENV infections (symptomatic or 211 
inapparent) during their time in the cohort or were classified as DENV-immune if 212 
they either entered the cohort with detectable anti-DENV EI antibodies or entered 213 
the cohort study with no detectable anti-DENV antibodies and had one or more 214 
documented DENV infections during their time in the cohort. All Zika suspected 215 
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 11 
cases were confirmed by RT-PCR in serum and/or urine using triplex assays that 216 
simultaneously screen for DENV and CHIKV infections (ZCD assay (42), CDC 217 
Trioplexor in some cases the CDC ZIKV monoplex assay(20) in parallel with a DENV-218 
CHIKV multiplex assay(41)).  The PDCS was approved by the Institutional Review 219 
Boards of the Nicaraguan Ministry of Health and the University of California, 220 
Berkeley. Parents or legal guardians of all subjects provided written informed 221 
consent, and subjects ≥6 years old provided assent. 222 
 223 
Samples from ZIKV virus infected US travellers  224 
Blood samples were collected at the University of North Carolina, University of 225 
Miami, Vanderbilt University and the National Institute of Health, from patients 226 
displaying symptoms of a suspected ZIKV infection following return to the US from 227 
ZIKV endemic areas. One donor had not traveled outside of the US and thus locally 228 
acquired ZIKV infection in Miami, FL. All samples were screened for previous DENV 229 
exposure by measuring DENV-specific serum IgG titers and/or neutralizing 230 
antibodies. Depending on the time of sample collection post onset of symptoms, 231 
samples were either classified as acute or convalescent as described above. 232 
 233 
PBMC isolation  234 
Peripheral blood mononuclear cells (PBMC) were isolated by density-235 
gradient sedimentation using Ficoll-Paque (Lymphoprep, Nycomed Pharma, Oslo, 236 
Norway) as previously described (44). Isolated PBMC were cryopreserved in cell 237 
recovery media containing 10% DMSO (Gibco), supplemented with 10-50% heat 238 
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 12 
inactivated fetal bovine serum, depending on the processing laboratory, (FBS; 239 
Hyclone Laboratories, Logan UT) and stored in liquid nitrogen until used in the 240 
assays. PBMC collected in Sri Lanka were stored in Synth-a-Freeze 241 
Cryopreservation medium (Cat A1254201 Thermo Fisher Scientific, USA). 242 
Volunteers from the National Institutes of health were enrolled into protocol 243 
VRC200 (NCT00067054) and leukapheresed. PBMC were processed and 244 
cryopreserved as described previously (22). 245 
 246 
Serology  247 
In general, DENV seropositivity was determined by DENV IgG or an 248 
Inhibition ELISA, as previously described(14, 16). Flow cytometry-based or Vero 249 
cell-based focus reduction neutralization assays were performed for further 250 
characterization of Pos. donors, as previously described (18, 38).  251 
 252 
rRT-PCR assays for ZIKV determination  253 
RNA was extracted from serum or urine using the QIAamp Viral RNA Mini kit 254 
(Qiagen). Samples were tested for ZIKV, and/or DENV using the ZCD assay, as 255 
previously described(42). DENV-pos. samples were serotyped, using a serotype-256 
specific DENV multiplex assay(40, 42). In some laboratories samples were tested by 257 
RT-PCR for ZIKV as previously described(20). At BSRI Blood donors were identified 258 
as ZIKV RNA pos. through routine donor screening using the cobas Zika test (Roche 259 
Molecular Systems, Inc., Pleasanton, CA (RMS) under IND. 260 
HLA typing 261 
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 13 
 Donors were HLA typed by an ASHI-accredited laboratory at Murdoch 262 
University (Western Australia) as previously described(45). HLA typing was 263 
performed for Class I (HLA A; B; C) and Class II (DQA1; DQB1, DRB1; DPB1) using 264 
locus-specific PCR amplification on genomic DNA. Primers used for amplification 265 
employed patient-specific barcoded primers. Amplified products were quantitated 266 
and pooled by subject, and up to 48 subjects were pooled. An unindexed (454 267 
technique 8-lane runs) or indexed (8 indexed MiSeq technique runs) library then 268 
was quantitated using kappa universal qPCR library quantification kits. Sequencing 269 
was performed using either a Roche 454 FLX+ sequencer with titanium chemistry or 270 
an Illumina MiSeq using a 2 x 300 paired-end chemistry. Reads were quality-filtered 271 
and passed through a proprietary allele-calling algorithm and analysis pipeline 272 
using the latest IMGT HLA allele database as a reference. 273 
 274 
MHC class I binding predictions and peptide selection 275 
 The BeH818995 ZIKV isolate (GenBank accession no. AMA12084.1) was used 276 
to perform ZIKV peptide selection. We selected a set of 9- and 10-mers ZIKV 277 
peptides predicted to bind one or more of 27 HLA class I A and B allelic variants 278 
chosen because of their high prevalence in the general population, as previously 279 
described(44). Class I binding predictions were done with Tepitool using the 280 
consensus method(26) (23). For each allele, and considering 9- and 10-mers 281 
separately, the top 2% scoring peptides (n=68) based on predicted percentile rank 282 
were selected; the final set synthetized had 1836 (68 X 27) 9-mers and 10-mers 283 
each, for a total of 3672 peptides (A&A, San Diego, CA).  For screening studies, the 284 
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class I peptides were combined into pools of approximately 10 to 11 individual 285 
peptides, according to their predicted HLA restriction, resulting in approximately 13 286 
pools per HLA allele. Table 2 lists the number of peptides synthetized for each allele 287 
as a function of protein of provenance. In addition, we synthetized a panel of 15-mer 288 
peptides, overlapping by 10 residues, spanning the entire sequence of the ZIKV 289 
BeH818995 isolate. The sequence homology between ZIKV and DENV for each 290 
protein is listed in Table 3. For screening studies, these peptides were combined 291 
into 10 megapools of 25-180 peptides according to the ZIKV protein from which 292 
they were derived (C, prM, E, NS1, NS2A, NS2B, NS3, NS4A+2k, NS4B, NS5). For 293 
deconvolution studies, pos. peptide pools were deconvoluted to identify individual 294 
epitopes, often going to an intermediate step of screening smaller pools before the 295 
individual peptide tests.  To assess DENV reactivity pools of previously identified 296 
and described DENV epitopes were utilized (i.e. DENV megapools, see 297 
references(45, 48)). Epitopes identified in this study have been submitted to the 298 
Immune Epitope Database (IEDB; Submission ID_1000720). 299 
 300 
IFNγ ELISPOT assay 301 
 A total of 20 x 104 PBMC were incubated in triplicate with 0.1 ml complete 302 
RPMI 1640 medium in the presence of peptide pools [1 μg/ml] or individual 303 
peptides [10 μg/ml]. Following a 20 h incubation at 37°C, the plates were incubated 304 
with biotinylated IFNγ mAb (mAb 7-B6-1 Mabtech, Stockholm, Sweden) for 2h and 305 
developed as previously described (44, 47).  In CD4 experiments, CD8 cells were 306 
depleted before incubation using magnetic beads and pos. selection (MACS Miltenyi 307 
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 15 
Biotec, Auburn, CA). Cells from donors with PHA values below 250 SFC / 106 PBMC 308 
have been excluded from the analysis.  309 
 310 
Flow Cytometry  311 
 Detailed information of all monoclonal antibodies used in this study is listed 312 
in Table 4. For the intracellular cytokine staining, PBMC were cultured in the 313 
presence of HLA-matched peptide pools [1 μg/ml] and Golgi-Plug containing 314 
brefeldin A (BD Biosciences, San Diego, CA for 6 hours and subsequently 315 
permeabilized, stained and analyzed with the same monoclonal antibody panel as 316 
described previously (44). Cells from donors have been excluded from the analysis if 317 
the IFNγ response to PMA and ionomycin stimulation was lower than 1% in the 318 
CD3+ cells. All data shown are background subtracted. 319 
 320 
Statistical analysis 321 
All statistical analyses were performed using the program Prism 7 (Graph-Pad 322 
Software, San Diego, CA). Data are expressed as Geometric mean with 95% CI or 323 
percent of frequency and data comparison has been performed with Mann-Whitney 324 
or Fisher test respectively.   325 
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Results  326 
 327 
DENV T cell responses are cross-reactive with ZIKV peptides 328 
 To address the interplay between DENV- and ZIKV-specific T cell responses, 329 
we studied HLA-typed PBMC donations from Sri Lanka obtained between 2010 and 330 
2016. We also studied PBMC from Nicaraguan donors obtained between 2010 and 331 
2014, thus preceding the current ZIKV epidemic(8, 44, 48). To study CD8 responses, 332 
we selected nine DENV-Pos. donors who had been infected by DENV multiple times 333 
(secondary infections) based on serum neutralization titers and whose samples 334 
showed appreciable ex vivo response to a pool of previously defined CD8 DENV 335 
epitopes (CD8-megapool)(48). A similar approach was used for CD4 responses, 336 
retrieving 5 DENV Pos. donors with ex vivo responses to a previously defined DENV 337 
CD4-megapool(45). As neg. controls, we used PBMC from donors who were DENV 338 
neg. from the same sites. 339 
 We tested PBMC from these groups for reactivity against ZIKV peptides in ex 340 
vivo IFNγ ELISPOT assays. In the case of CD8 T cell responses (HLA class I), we 341 
tested panels of ZIKV-derived peptides predicted to bind each donors HLA 342 
molecules(44). HLA restrictions were assigned based on testing short 9-10 mers 343 
that are predicted to bind with high affinity to the HLA allotypes of the responding 344 
donors. In the case of CD4 T cell responses (HLA class II), we tested a panel of 684 345 
overlapping peptides spanning the entire ZIKV proteome. CD8-depleted PBMCs 346 
were used in these experiments to avoid inadvertently identifying CD8 epitopes 347 
nested in the 15mer peptide tested. In both cases, peptide pools were tested, and the 348 
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total reactivity observed in each donor was recorded. The peptide sets used in this 349 
study are summarized in Table 2. 350 
 As expected for CD8, T cells from the DENV neg. donors did not respond to 351 
either the previously defined DENV epitopes, nor to the ZIKV peptides. The cells 352 
were viable and responsive to stimulation, as shown by vigorous responses to PHA 353 
mitogen stimulation. Interestingly, CD8 T cells from one third of  the DENV-Pos. 354 
donors recognized ZIKV-derived peptides (Figure 1A). Higher level of cross-355 
reactivity emerged from the study of the CD4 T cells, as ZIKV derived peptides were 356 
recognized by CD4 T cells from 4 out of 5 DENV-Pos. individuals (Figure 1B).  357 
 In a further series of experiments, we analyzed responses from two 358 
additional cohorts of donors, a cohort of donors recently vaccinated with a 359 
Tetravalent Dengue Attenuated Vaccine (TDLAV) and a control cohort of donors 360 
negative for responses to DENV and other flaviviruses provided for the University of 361 
Vermont Clinical site. Responses against the DENV CD8-megapool and pools of ZIKV 362 
predicted peptides matching the HLA A and B alleles expressed in each donor were 363 
tested in IFN-gamma ICS assays (Figure 1C). CD8 T cells from the Flavivirus neg. 364 
donors did not respond to either the previously defined DENV epitopes, nor to the 365 
ZIKV peptides. By contrast CD8 T cells from TDLAV donors recognized, as expected 366 
the DENV CD8 megapool, but also in more than 50% of the cases the ZIKV-derived 367 
peptides. In conclusion, analysis of ex vivo responses of ZIKV naive and DENV Pos. 368 
donors revealed substantial cross-reactivity to ZIKV derived peptides.  369 
  370 
Identification of ZIKV epitopes cross-reactive with DENV responses 371 
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 Individual epitopes were mapped in representative cases. Where sufficient 372 
cell numbers were available, pos. pools were deconvoluted to identify ZIKV-specific 373 
epitopes across the ZIKV genome including all structural and nonstructural (NS) 374 
proteins. The mapping of CD4 and CD8 response was performed by sequential 375 
testing of pools and deconvolution to identify the positive peptides (Figure 2A). The 376 
HLA-B*35:01 CD8 epitope encoded by ZIKV NS32867-2876 was recognized by PBMC 377 
from a DENV-Pos. Nicaraguan donor (Figure 2B). This epitope was found to be 378 
highly similar (a single Y>F substitution) in DENV1-4 serotypes consensus 379 
sequences obtained as previously described(44). A Sri Lankan donor recognized the 380 
B*07:02 ZIKV NS31725-1734 epitope (Figure 2C). The same epitope was also 381 
recognized by a different DENV-Pos. Sri Lankan donor (Figure 2D). The identical 382 
sequence was found in DENV2, 3 and 4. 383 
 In the case of CD4 (Figure 2E), the ZIKV NS52986-3000 epitope, 100% 384 
conserved in DENV1-4 sequences, was recognized by PBMC from a DENV-Pos. Sri 385 
Lankan donor. PBMC from a Nicaraguan donor recognized the ZIKV NS1986-1000 386 
epitope (Figure 2F). Here, the recognized 15 mer contained a core NS1989-998 387 
sequence that was also highly conserved in all DENV serotypes, with A>S and M>L 388 
conservative substitutions. A different pattern was observed for the ZIKV E486-500 389 
epitope, which was recognized by PBMC from a different DENV-Pos. Nicaraguan 390 
donor (Figure 2G). In this case the most homologous 9-mer (sequence 391 
LYYLTMNNK), shared only 4 identities, with DENV1 sequences, 2 are conservative 392 
(L>M and N>E) and 3 semiconservative (Y>V, Y>L and K>N) substitutions. 393 
Additional sequence homology analysis using Genbank sequences did not reveal any 394 
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sequences with higher homology from other common flaviviruses, such as JEV, 395 
WNV, DENV, and YFV. 396 
 In conclusion, in 5 out of 6 instances the cross-reactivity from the DENV-pos. 397 
(and presumably ZIKV-neg.) donors was directed to ZIKV sequences found to be 398 
identical or highly conserved with sequences in DENV serotypes.  399 
 400 
Recruitment of donor cohorts differing in ZIKV and DENV pre-exposure status  401 
 To address the effect of pre-existing immunity on T cell responses to 402 
secondary flavivirus infection, we investigated six donor groups, namely ZIKV acute, 403 
convalescent or neg., and for each of these cohorts we further subdivided our 404 
cohorts into DENV-Pos. or -neg. individuals. For the purpose of classification in the 405 
various cohorts, the following criteria were used. Infection with ZIKV was confirmed 406 
using RT-PCR performed on acute infection samples as described in more detail 407 
below. Depending on the time of sample collection after the onset of symptoms or 408 
ZIKV RNA-pos. blood donation, samples were either classified as acute or 409 
convalescent as described in more detail in Materials and Methods. ZIKV negativity 410 
was inferred based on donations being obtained before- or outside of the area 411 
affected by the epidemic. DENV pos. or neg. status was determined on the basis of 412 
IgG status at the time of clinical presentation or blood donation, or in the case of the 413 
Nicaraguan samples, from documented history of DENV infection in the longitudinal 414 
cohort study. The subjects studied spanned a very diverse breadth of ethnicities and 415 
clinical sites, including Brazil (Rio de Janeiro and Sao Paulo), Nicaragua, Puerto Rico, 416 
Mexico, returned US travelers, and a US flavivirus-neg. cohort. The general features 417 
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of the subjects are detailed in Table 1. The relative proportion of females across all 418 
cohorts was 60% and the average age was 34 (range 3-70).   419 
ZIKV-specific responses are modulated by previous DENV exposure 420 
 Next, we compared ZIKV T cell reactivity in the subjects described above as a 421 
function of ZIKV status (i.e. neg., acute infection or convalescent status), and also 422 
considering prior DENV infection as a variable. To assess T cell reactivity, we 423 
devised a strategy to account for the fact that in most cases the amount of PBMC was 424 
limiting. Accordingly, the overlapping 15-mers spanning the entire ZIKV proteome 425 
were divided into ten pools corresponding to the ten encoded ZIKV proteins. 426 
Intracellular cytokine staining (ICS) assays and CD8/CD4 gating allowed assessment 427 
of CD8 and CD4 responses in parallel without the need to know the HLA phenotype 428 
of the donor.  All the ZIKV CD8 responses in ZIKV samples have been assessed using 429 
these pools of overlapping peptides and gating on CD8+ responding T cells in the ICS 430 
assay. In a few instances where the number of PBMC available from each donor did 431 
not allow testing of all pools, a factorial design was utilized: while not all pools were 432 
tested in all donors, all pools were tested in the same number of donors. Whenever 433 
sufficient cell numbers were available, pos. pools were deconvoluted, and specific 434 
epitopes identified. Overall, PBMC from 17-33 donors/patients were tested for each 435 
of the different categories (Table 5). 436 
The frequency of ex vivo responses in ZIKV-infected patients was 30-40% for 437 
both CD4 and CD8 responses, with the exception of CD8 responses in acutely 438 
infected donors, which were detected in approximately 90% of the cases (Figure 3A 439 
and D left panels). Marginal CD8 responses to the ZIKV peptides were noted in the 440 
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case of the ZIKV-neg. DENV-neg. donors (Figure 3A). However, ZIKV-neg. DENV-441 
Pos. donors showed appreciable reactivity both in terms of increased frequency and 442 
magnitude of responses, confirming a degree of T cell cross-reactivity between 443 
DENV-ZIKV responses observed above (Figures 1 and 2). In the acute ZIKV-444 
pos./DENV-Pos. donors, CD8 responses to ZIKV peptides were of significantly higher 445 
magnitude compared to those acute ZIKV subjects who were DENV neg. (Figure 3B 446 
and C). After ZIKV convalescence, the CD8 responses to ZIKV-restricted peptides 447 
were still elevated as compared to ZIKV-neg. donors, but were not significantly 448 
different by DENV serostatus (Figure 3B and C). The pattern of CD4 responses to 449 
ZIKV-restricted class II peptides was remarkably similar with regard to ZIKV acute 450 
and convalescence phase and impact of DENV seropositivity, with trends for ex vivo 451 
ZIKV T cell responses being delayed in DENV neg. donors and lower frequency and 452 
magnitude of responses observed in respect to the CD8 counterpart. (Figure 3D-F). 453 
   454 
Different proteins are targeted by ZIKV versus DENV immunity 455 
 We next determined whether DENV serostatus affected the antigenic targets 456 
of ZIKV-reactive T cells across the ZIKV polyprotein.  A breakdown of ZIKV CD8 457 
responses in acute and convalescent ZIKV pos. donors (combined in this plot) as a 458 
function of the antigen targeted is presented in Figure 4. In the case of ZIKV-specific 459 
CD8 responses in DENV-neg. donors 57% of the response was directed against 460 
structural proteins (Figure 4A). In the context of a previous DENV-exposure, 461 
however, only 30% of the ZIKV-specific responses were directed against structural 462 
proteins (Figure 4B). This can be compared to historical data regarding DENV 463 
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responses from presumably ZIKV-neg. donors (since samples were collected prior to 464 
the 2015-2016 ZIKV epidemic) where only 14.9% of the response was directed 465 
against structural proteins(44). Thus, the CD8 response to ZIKV is more focused on 466 
structural proteins compared to the focus on nonstructural proteins by DENV-467 
specific T cells. Nonetheless, DENV pre-exposure modulates the ZIKV-reactive 468 
immunodominance pattern for CD8 cells, resulting in a broad recognition across the 469 
ZIKV proteome. 470 
 In the context of CD4, responses were directed in approximately equal 471 
proportions against structural and non-structural proteins (Figure 4B). Differences 472 
between DENV and ZIKV patterns of immunodominance were not prominent, which 473 
was not surprising since, according to published data, the DENV-specific response is 474 
already focused almost equally (50%) on structural and non-structural 475 
proteins(45). In the present study, the fraction of ZIKV-specific responses directed 476 
against structural proteins was 58% or 67% for DENV-neg. subjects and DENV-Pos. 477 
ZIKV-pos. donors, respectively (Figure 4C-D). 478 
 As above, whenever possible, peptides pools were deconvoluted and specific 479 
epitopes mapped using same mapping approach previously shown in Figure 2A. 480 
Two ZIKV NS5 epitopes (NS52819-2828 and NS52868-28876) both predicted to be 481 
restricted by HLA B*35:01, were recognized in an HLA matched DENV Pos. donor 482 
(Figure 5A-B). One of these epitopes was independently identified in a DENV-Pos., 483 
ZIKV-neg. donor (Figure 2B). In both cases, the ZIKV epitope differed from DENV 484 
sequences by a single conservative substitution. A second DENV pos. donor 485 
responded to the ZIKV ENV719-728 epitope (predicted B*40:01 restriction), which 486 
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differs from DENV3 sequences by one single conservative substitution (Figure 5C). 487 
Another E protein epitope was identified in the same donor (E481-495; restricted by 488 
HLA A*01:01), which in this case had more limited homology to DENV sequences 489 
(Figure 5D).  490 
 Independent experiments showed that the very same ZIKV E485-493 HLA 491 
A*01:01 epitope also was recognized in a DENV-neg. subject (Figure 5E; Ricciardi et 492 
al. manuscript submitted). Interestingly longer version of this peptide were not 493 
recognized. It is possible that both 9 mer and 10 mer bind with high affinity, but in 494 
somewhat different registers. Additional epitopes recognized in DENV-neg. donors 495 
were mapped to a ZIKV C23-32 epitope restricted by HLA A*03:01, showing again 496 
limited homology to DENV sequences, and two additional ZIKV NS3 epitopes 497 
restricted by HLA B*0801 and B*41:02 (Figure 5F-H). Additionally, we selected two 498 
ZIKV peptides TPYGQQRVF and APTRVVAAEM that were recognized by DENV 499 
seropositive donors (Figures 2A-C), and synthetized the corresponding DENV 500 
peptides. These peptides were then tested in parallel with the original ZIKV 501 
peptides with PBMCs from the donor originally utilized to map the responses in 502 
standard IFN-γ Elispot assays. Likewise we also tested the ZIKV ENV GLDFSDLYY 503 
epitope defined in a DENV seronegative donor (Figure 5E), and tested the 504 
corresponding DENV peptides in parallel with the originally identified ZIKV peptide. 505 
The ZIKV TPYGQQRVF and APTRVVAAEM peptides as well as the corresponding 506 
highly homologous DENV TPFGQQRVF and APTRVVASEM peptides were recognized 507 
by the DENV seropositive donor with comparable magnitude. In contrast, the ZIKV 508 
Env GLDFSDLYY, but not the fairly discordant corresponding DENV epitopes 509 
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GLDFNEMVL and GIDFNEMVL were recognized by the DENV seronegative donor 510 
response (Table 6). 511 
 512 
Phenotype analysis of CD8 T cell responsive to ZIKV peptides 513 
 To gain further insights into the potential biological significance of these 514 
patterns of reactivity, we determined cell surface phenotypes of the CD8 T cells 515 
producing IFNγ in response to the ZIKV peptide pools. As expected (Figure 6A), 516 
these cells were predominantly TEM (CCR7+CD45RA-; approximately 60% on 517 
average) and TEMRA (CCR7+CD45RA+; approximately 30% on average). 518 
Approximately 50% of the IFNγ+ CD8 T cells were TNFα+ as compared to less than 519 
1% of the IFNγ- cells (Figure 6B), thus establishing that a large fraction of the 520 
responding cells are polyfunctional.  Similar patterns were observed for 521 
ZIKA+DENV- and ZIKA+DENV+ donors in terms of both memory phenotypes and 522 
polyfunctionality. 523 
 By contrast, significant differences were seen between ZIKA+DENV- and 524 
ZIKA+DENV+ donors when the granzyme B and PD1 markers were considered. The 525 
expression of granzyme B in CD8 T cells from ZIKA+DENV- was not significantly 526 
increased in IFNγ+ cells as compared to the background level of approximately 30% 527 
seen in IFNγ- cells, while in the case of ZIKA+DENV+ approximately 80% of the 528 
IFNγ+ cells were also granzyme positive (Figure 6C). Similarly, PD1 was only mildly 529 
expressed in IFNγ+ cells from ZIKA+DENV-, while 60% on average of the 530 
ZIKA+DENV+ IFNγ+ cells also upregulated PD1 (Figure 6D). These data indicates 531 
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that DENV pre-exposure affect not only the quantity but also the quality of 532 
responses observed following ZIKV infection. 533 
  534 
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Discussion  535 
 We report the first characterization in humans of both ZIKV-specific and 536 
ZIKV/DENV cross-reactive T cell responses, and the influence of DENV serostatus on 537 
T cell immunity to ZIKV.  Our study established three main points. First, pre-existing 538 
T cell responses against DENV recognize peptide sequences encoded in the ZIKV 539 
proteome. Second, cross-reactivity is immunologically consequential, as DENV-Pos. 540 
individuals at the time of ZIKV infection respond more strongly to ZIKV both in 541 
terms of CD4 and CD8 T cell responses. Third, patterns of immunodominance are 542 
different in the case of DENV and ZIKV infection with, ZIKV-specific CD8 T cell 543 
responses predominantly targeting structural proteins such as E, prM, and C. Our 544 
study involves samples form ZIKV-infected donors derived from a variety of 545 
different geographical locations, including mainland USA (travelers returning from 546 
affected areas), Puerto Rico, Brazil, Nicaragua, and Mexico. As such we believe that 547 
the pattern of responses we observed is of general relevance, and not limited to a 548 
specific population or clinical context. In the present study we did not isolate 549 
representative viruses from the different cohorts and compared the sequences in 550 
terms of the percentage of similarity/differences to the peptide libraries used. Thus, 551 
it is possible that intra ZIKV sequence variation might influence some of the results, 552 
which should be interpreted with this caveat in mind. 553 
 We established that DENV-specific memory T cells recognize peptide 554 
sequences encoded in the ZIKV proteome. This point was established with a 555 
separate set of PBMC donations obtained either in Sri Lanka, where ZIKV has not 556 
been reported, as well as from Nicaragua collected between 2010 and 2014 before 557 
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the introduction of ZIKV into the country. In this study we did not test recognition of 558 
the DENV peptides corresponding to the ZIKV epitopes. We note this limitation in 559 
our interpretation, as for example, recognition of the corresponding DENV peptide 560 
could be much higher than for the ZIKV peptide. The molecular basis of this cross-561 
reactivity was established by mapping several different CD4 and CD8 epitopes. 562 
These epitopes represent the first mapping of DENV/ZIKV cross-reactive epitopes in 563 
humans, and in most cases the cross-reactivity could be explained by identity or 564 
high similarity to sequences previously identified in one or more DENV serotypes. 565 
This finding was predicted by previous analysis conducted by the IEDB analysis 566 
resource(53), and by a recent study utilizing HLA transgenic mice (51). Nonetheless, 567 
identification of specific sequences here allows for a comprehensive assessment of 568 
whether the cross-reactivity is focused on regions that are highly conserved. Most 569 
importantly, we demonstrate that DENV-specific CD8 responses induced by TDLAV 570 
vaccination recognize ZIKV derived peptides. This cross-reactivity indicates a 571 
potential for the TDLAV to provide some degree of protection against ZIKV infection.  572 
 An average homology level of 77% was observed between the sequences of 573 
DENV and ZIKV cross-reactive epitopes (defined as ZIKV sequences recognized in 574 
DENV-Pos. donors), as compared with an overall 56% level of homology detected 575 
when the overall sequences of ZIKV and DENV proteomes were compared (Table 576 
3). We conclude that sequential exposure to DENV and ZIKV sequences 577 
preferentially expands responses against conserved sites between the viruses. 578 
Similar observations were made in previous studies that showed that secondary 579 
DENV infections are associated with preferential recognition of epitopes conserved 580 
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amongst different DENV serotypes that showed that secondary DENV infections are 581 
associated with preferential recognition of epitopes conserved amongst different 582 
DENV serotypes(44). Also, sequential exposure to different DENV serotypes in 583 
animal DENV models results in expansion of T cells recognizing cross-reactive 584 
epitopes (12, 46).  It would have been interesting to examine if primary versus 585 
secondary DENV infection or the time interval between DENV and ZIKV infection 586 
influences T cell responses to ZIKV peptides. However this information is not 587 
available to us from all different sites and an analysis of this variable could be 588 
addressed in future studies specifically designed to examine this issue. 589 
 It is also noteworthy that three out of eleven of the identified epitopes were 590 
identified in multiple independent donors (ZIKV NS3-1725-1734, NS52868-2876 and E485-591 
493).  Albeit based on a limited number of subjects, these results indicate that ZIKV 592 
responses may be associated with strong immunodominance of particular epitopes.  593 
In addition, NS52868-2876 was identified in DENV+ZIKV+ and DENV+ZIKV- individuals 594 
but no reactivity was detected in pools containing this peptide in DENV-ZIKV+ 595 
donors. Conversely, ZIKA E485-493 with lower homology level with DENV, was 596 
identified in DENV+ZIKV+ and DENV-ZIKV+ individuals but not in DENV+ZIKV- 597 
donors.  598 
Significant differences in frequency or magnitude of T cell responses to ZIKV 599 
peptides in PBMCs from ZIKV-DENV+ donors compared with ZIKV-DENV- donors 600 
were detected in the acute phase of infection with ZIKV. This parallels similar 601 
observations made in terms of antibody responses that showed that ZIKV/DENV 602 
cross reactivity is most readily detected close to infection and wane afterwards (7). 603 
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We also find that DENV pre-exposure influences ZIKV responses. This could be 604 
understood in the context of the well recognized phenomenon of heterologous 605 
immunity(32, 50). Specifically, ZIKV-specific T cells responses for both CD4 and CD8 606 
T cells responses develop more rapidly in DENV-Pos. individuals and are already 607 
apparent in the acute phase of the disease. These responses subside at 608 
convalescence, but remain elevated compared to those in ZIKV-neg. individuals. The 609 
percentage of subjects with confirmed ZIKV infection who showed a positive T cell 610 
response (Figures 3A and 3D) is relatively low, consistent with a primary infection 611 
and with ZIKV being in most cases associated with a milder clinical presentation 612 
than DENV(46). This pattern is reflective and characteristic of the differences in a 613 
primary compared to a classic secondary response (55).  Here we demonstrate how 614 
prior DENV infection alters ZIKV-specific immune responses and we provide the 615 
first evidence that prior DENV infection leads to stronger and faster responses thus 616 
providing evidence of a biological outcome. This is the first evidence in humans that 617 
previous exposure to dengue virus can influence subsequent infection with ZIKA 618 
virus by mounting a cross-reactive memory T cell response against ZIKA virus. 619 
Recent data in HLA transgenic mice demonstrated that ZIKV challenge following 620 
immunization of mice with ZIKV-specific and ZIKV/DENV cross-reactive epitopes 621 
elicited CD8+ T cell responses that reduced infectious ZIKV levels, and CD8+ T cell 622 
depletions confirmed that CD8+ T cells mediated this protection (51). In addition a 623 
recent paper has shown that Zika virus pathogenesis in rhesus macaques is 624 
unaffected by pre-existing immunity to dengue virus (25). Together these data 625 
underline important implications for ZIKV vaccine development. 626 
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We have previously shown that stronger T cell responses are associated with 627 
certain HLA alleles associated with protection in case of heterologous infection with 628 
DENV pointing to a protective effect of these cross-reactive responses (44). Given 629 
that the groups were drawn from different study populations (age and genetic 630 
background), which could influence the magnitude of the T cell responses further 631 
studies will provide more evidence on the generality of our findings. It remains to be 632 
seen whether this effect will be mimicked by DENV-or ZIKV-vaccination. 633 
Importantly, our data indicates that DENV pre-exposure also alters the quality of 634 
responses. While no difference was seen between DENV pre-exposed and DENV-635 
naïve donors at the level of composition of memory subsets in the responding cells 636 
or the degree of multifunctionality, DENV specific CD8 responses from DENV pre-637 
exposed donors significantly upregulated granzyme B and PD1, suggesting a more 638 
differentiated phenotype, similar to what detected in secondary DENV infection (6, 639 
8). 640 
Our data provide an example of adaptive heterologous immunity, where 641 
cross-reactive memory Dengue-specific CD8 T cells are enhancing the T cell 642 
responses to ZIKA virus. At this time these studies do not yet address whether this 643 
will be beneficial in the majority of cases while at other times it could be detrimental 644 
based on the specific cross-reactive pattern of each patient. However identifying key 645 
cross-reactive epitopes in humans and demonstrating that they influence the 646 
characteristics of the subsequent T cell response to ZIKA virus as this study does is 647 
an important step, toward understanding potential immunopathology in ZIKA virus 648 
infection. 649 
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An unexpected result of our analysis is that almost 60% of the ZIKV-specific CD8 650 
responses in ZIKA-pos. but DENV-neg. individuals are directed against structural 651 
proteins. This is in contrast to the relative paucity of structural protein-directed T 652 
cell responses observed in DENV infection where only 15% of CD8 T cell responses 653 
are directed against structural proteins (44), even though serotype specific 654 
differences have been noted (1, 2, 43, 44, 46).  Interestingly, the percentage of CD8 T 655 
cell responses directed against structural proteins in DENV-Pos. ZIKV patients is 656 
30%, thus suggesting that previous DENV exposure may alter the patterns of 657 
immunodominance, skewing it towards a pattern more similar (but still not 658 
identical) to that observed in DENV Pos. donors in absence of ZIKV infection.  659 
The degree of homology (conservation) between NS proteins of DENV and ZIKV is 660 
on average 51%, compared to 49% for structural proteins and 58% compared to 661 
51% when accounting for size difference, so a higher degree of homology does not 662 
itself drive or focus cross-reactive responses on these antigens. The conclusion that 663 
T cell epitopes for ZIKV and DENV differ in their distribution between structural and 664 
non-structural proteins requires the caveat that is based on comparing data 665 
generated in separate studies, which have used different methods (e.g., ELISPOT 666 
versus flow cytometry). In addition, It can not be excluded that the strong 667 
magnitude of one donor may have an substantial effect on the percent of the total 668 
response directed towards nonstructural proteins.   669 
It would have been of interest to determine the number of epitopes detected in the 670 
structural and nonstructural regions on a per donor basis. This analysis could 671 
provide additional support for the notion that pre-existing immunity to DENV 672 
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broadens recognition across the ZIKV proteome. Due to the small volume of blood 673 
samples collected we were not able to deconvolute all positive pools to identify the 674 
exact epitope. Future studies where larger amounts of blood are collected will allow 675 
to comprehensively address this point. It is also worth noting that significant CD8+ 676 
responses directed against structural proteins were reported in the case of West 677 
Nile and Japan Encephalitis (21, 39). These two flaviviruses are both associated with 678 
neurological complications(34). Further, we previously shown in an HLA-transgenic 679 
model a trend towards higher recognition of structural proteins for DENV3 (as 680 
compared to other DENV strains)(46), which previously also was reported to be 681 
associated with neurological symptoms(10, 35).  Similarly, we have previously 682 
shown that human DENV3-serotype specific CD8+ T cell responses preferentially 683 
recognize structural proteins. Conversely, DENV 1 and DENV4 serotypes 684 
preferentially recognized non-structural proteins. Finally DENV2 serotype showed a 685 
broader recognition of all proteins but still elicited the strongest CD8+ T cell 686 
response against non-structural proteins(48). As no higher level of homology is 687 
observed between ZIKV and DENV3 respect to the other DENV serotypes that could 688 
explain the preferential recognition of structural proteins (Table 3), we could 689 
hypothesize that common processing pathways or similar CD8+ T cell elicitation 690 
might occur that differs from the other DENV serotypes and will need further 691 
investigation.  692 
 Mapping of over ten different ZIKV epitopes suggest that DENV-Pos. donors 693 
tend to recognize DENV/ZIKV highly conserved epitopes, while DENV neg. subjects 694 
may recognize more divergent targets. An average 76% level of homology existed 695 
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between DENV and ZIKV sequences among cross-reactive epitopes (defined as ZIKV 696 
sequences recognized in DENV-Pos. donors), as compared with an average 55% 697 
level of homology between DENV and ZIKV sequences at the level of ZIKV epitopes 698 
recognized in DENV-neg. donors, and an overall 56% level of homology detected 699 
when the overall sequences of ZIKV and DENV proteomes were compared. These 700 
results emphasize that previous exposure to DENV influences the fine repertoire of 701 
epitopes being recognized. It remains to be seen if cross-reactivity of T cells can also 702 
be detected between ZIKV and other related flaviviruses. In the present study we 703 
have not characterized WNV or JEV exposure. It is possible that cross reactivity at 704 
the T cell level may exist between ZIKV and other more distantly related 705 
flaviviruses, and this point will be address in future studies. 706 
 In the majority of cases, the degree of homology between ZIKV and DENV 707 
was very high, suggesting that a ZIKV diagnostic assay based on T cell responses is 708 
not immediately practical, and conversely reemphasizing that DENV pre-exposure 709 
(or vaccination) might influence ZIKV immunity. Vaccines against ZIKV that are 710 
currently under development and focus on structural protein antigens rather than 711 
live virus may have logistical (no need for cold chain) and safety (no risk of virulent 712 
reversion and safe to administer to pregnant and immune-compromised patients) 713 
advantages; however, these vaccines may not comprise the full set of antigens 714 
required to induce protective immunity. Our results that approximately 55-60% of 715 
the ZIKV-specific CD4 and CD8 response is directed against structural proteins is 716 
encouraging that cellular responses necessary to directly limit ZIKV infection and 717 
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support T-dependent antibody responses may be achievable with vaccine 718 
approaches being pursued. 719 
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Figure Legends 972 
Figure 1. Ex-vivo reactivity to ZIKV derived peptides and previously defined 973 
DENV epitopes in DENV-Pos., -neg. donors and DENV vaccines.  CD8 (A) and CD4 974 
(B) T cell reactivity to DENV epitopes and ZIKA peptides in ELISPOT ex-vivo 975 
experiments are shown for donors DENV Pos. (red) or neg. (black). Responses were 976 
expressed as the number of IFN secreting cells per 106 PBMC and were considered 977 
pos. if the net spot-forming cells (SFC) per 106 were 20, had a stimulation index of 978 
2, and a p<0.05 in a t test or in Poisson test comparing replicates with those from 979 
the neg. control. Donors with PHA values <250 SFC per 106 PBMC have been 980 
excluded from the analysis. Data are expressed as geomean with 95% CI. CD8 (C) T 981 
cell reactivity to DENV megapool and ZIKA HLA-restricted pools in ICS experiments 982 
are shown in DENV vaccinees (green) in comparison with flavivirus naïve donors 983 
(black). Data are expressed as average ± SD of the percentage of CD3+CD8+IFNγ+ 984 
cells.  985 
 986 
Figure 2. Mapping of CD8 and CD4 cross-reactive DENV-ZIKV T cell epitopes. 987 
Panel A shows an example of the mapping strategy. CD8 (B-D) and CD4 (E-G) 988 
restricted epitopes were mapped by peptide deconvolution in ELISPOT ex-vivo 989 
experiments in individual donors.  ZIKV epitope sequences were aligned with 990 
consensus sequences of DENV1, 2, 3 and 4 serotypes. Amino acid mismatches 991 
between the ZIKV sequence and the DENV consensus sequences are shown in red.  992 
 993 
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Figure 3. Ex-vivo reactivity of ZIKV donors to ZIKV peptides. CD8 (A-C) and CD4 994 
(D-F) ZIKV-restricted responses in ZIKV-neg., acute and convalescent donors are 995 
shown in intra cellular cytokine experiments. Each group is further divided in 996 
DENV-Pos. (red) or -neg. (black). Each donor has been tested with at least 5 protein 997 
pools (C-NS2A or NS2B-NS5) or the full set of protein pools depending on the 998 
availability of cells (A-B; D-E). Each data points represents the response of a single 999 
donor response if all 10 protein have been tested or the combined response of two 1000 
donors tested with the two different sets of 5 protein pools. Panels C and F show all 1001 
the responses against individual pools regardless of the donor it has been tested. 1002 
Statistical significance for differences in frequency of responders (left panels) was 1003 
performed using a Fisher test. Magnitude of responses (central and right panels) is 1004 
expressed as geometric means with 95% CI, and statistical analyses were performed 1005 
with Mann-Whitney U test. 1006 
 1007 
Figure 4. Immunodominance pattern of CD8 and CD4 responses against ZIKV-1008 
derived peptides. ZIKV CD8 (A and B) and CD4 (C and D) responses to 10 ZIKV 1009 
proteins are shown in ZIKV-pos. DENV-neg. subjects (left panels, A and C), or DENV-1010 
Pos. subjects (right panels, B and D). Structural (C, prM, E) and non-structural (NS1, 1011 
NS2A, NS2B, NS3, NS4A, NS4B, NS5) proteins are divided by a dotted line, and their 1012 
magnitude in percentage shown in each graph. The total magnitude of the responses 1013 
has been calculated and the resulting percentage of responses for structural and non 1014 
structural proteins shown respectively in the upper left and right of each figure 1015 
panel. Data are expressed as geometric means with 95% CI.  1016 
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 1017 
Figure 5. Mapping of CD8 ZIKV epitopes in ZIKV-pos. donors. 1018 
ZIKV-restricted epitopes mapped by peptide deconvolution in ELISPOT ex-vivo 1019 
experiments in DENV-Pos. (A-D) or DENV-neg. (E-H) individuals.  ZIKV epitope 1020 
sequences were aligned with consensus sequences of DENV1, 2, 3 and 4 serotypes. 1021 
Amino acid mismatches between the ZIKV sequence and the DENV consensus 1022 
sequences are shown in red. Boxes indicate the optimal epitope restricted by the 1023 
specific HLA phenotype present in this donor. 1024 
 1025 
Figure 6. Phenotype characterization of CD8- ZIKV specific immune responses 1026 
in ZIKV -pos. donors. 1027 
Memory phenotype (A) and polyfunctionality (B-D) of ZIKV CD8 T cells were 1028 
compared in donors ZIKV-pos. DENV-neg (black) and ZIKV-pos. DENV-pos (red). A) 1029 
Average of percentage of memory phenotype populations (naïve: CD45RA+CCR7+, 1030 
central memory: CD45RA-CCR7+, effector memory: CD45RA-CCR7- and Temra: 1031 
CD45RA+CCR7-) in CD8-ZIKV specific IFNγ producing cells. IFNγ- (oblique lines) 1032 
and IFNγ+ (blank pattern) CD8 T cells were analyzed for the co-expression of TNFα 1033 
(B), Granzyme B (C) and PD1 (D). Data were expressed as average ± SD of the 1034 
percentage of CD3+CD8+ cells. Statistical analysis was performed with Mann-1035 
Whitney U test. * P<0.05, ** P<0.01, ***P<0.005, ****P<0.001.  1036 
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Table 1: General features of the ZIKV infected cohorts 1037 
Site Country # Age a) Sex b) DENV+ c) 
University of São Paulo Brazil 7 45 (25-61) 85 85 
Fundação Oswaldo Cruz Brazil 12 35 (22-60) 20 100 
PDCS d) Nicaragua 14 7 (3-14) 78 14 
REDSIII e) Puerto Rico/US 20 46 (21-70) 35 85 
Universidad Veracruzana Mexico 19 38 (6-69) 63 26 
University of North Carolina Unites States 8 37 (18-53) 71 50 
University of Miami United States 2 29(26-32) 100 50 
Vanderbilt University United States 9 42 (19-62) 56 11 
National Institutes of Health  United States 7 29 (26-40) 42 71 
Overall  98 34 (3-70) 60 54 
 1038 
a) expressed as the average age of the cohort (range) 1039 
b) expressed as the relative proportion of females in the cohort (%) 1040 
c) expressed as percentage of DENV Pos. individuals in the cohort  1041 
d) Pediatric Dengue Cohort Study  1042 
d) Recipient Epidemiology and Donor Evaluation Study-III 1043 
  1044 
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Table 2: ZIKV peptides used in this study 1045 
 1046 
a) ZIKV predicted peptide set composed by 9-and 10-mer peptides.  1047 
Allele C pr M E NS1 NS2A NS2B NS3 NS4A 2K NS4B NS5 Total 
HLA-A*01:01 0 10 5 21 6 8 6 21 4 0 17 38 136 
HLA-A*02:01 7 0 6 20 3 23 5 17 10 3 26 16 136 
HLA-A*02:03 9 0 6 16 3 23 8 20 9 4 23 15 136 
HLA-A*02:06 4 2 2 14 6 25 5 17 17 6 25 13 136 
HLA-A*03:01 12 4 4 11 10 17 4 22 5 0 8 39 136 
HLA-A*11:01 14 6 2 11 9 6 7 23 6 0 11 41 136 
HLA-A*23:01 5 2 4 20 7 7 1 21 7 0 21 41 136 
HLA-A*24:02 4 3 4 16 5 9 2 16 7 0 24 46 136 
HLA-A*26:01 6 5 1 15 6 10 15 16 9 3 17 33 136 
HLA-A*30:01 9 3 1 18 16 8 3 26 3 0 10 39 136 
HLA-A*30:02 1 10 5 17 11 2 8 24 1 0 21 36 136 
HLA-A*31:01 10 3 8 8 18 11 2 25 1 0 5 45 136 
HLA-A*32:01 6 3 6 21 9 18 6 16 7 1 11 32 136 
HLA-A*33:01 9 1 5 6 15 12 3 22 2 0 5 56 136 
HLA-A*68:01 9 4 5 12 13 8 3 35 3 0 7 37 136 
HLA-A*68:02 7 5 5 17 6 11 7 18 8 5 22 25 136 
HLA-B*07:02 4 2 6 12 15 16 5 35 6 2 11 22 136 
HLA-B*08:01 11 4 2 13 13 16 0 24 10 0 7 36 136 
HLA-B*15:01 4 7 7 18 6 12 7 17 6 1 23 28 136 
HLA-B*35:01 4 5 3 14 5 12 9 23 7 2 26 26 136 
HLA-B*40:01 2 4 4 17 17 4 8 25 10 0 6 39 136 
HLA-B*44:02 1 4 1 15 18 3 7 32 7 0 5 43 136 
HLA-B*44:03 3 3 2 14 20 3 7 33 7 0 4 40 136 
HLA-B*51:01 4 0 8 13 6 19 9 17 9 5 17 29 136 
HLA-B*53:01 6 3 2 18 13 12 6 18 8 2 17 31 136 
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HLA-B*57:01 3 5 4 15 16 12 3 13 4 0 13 48 136 
HLA-B*58:01 7 1 5 17 16 14 3 11 5 0 11 46 136 
Total 161 99 113 409 288 321 149 587 178 34 393 940 3672 
 1048 
b) 15-mer peptides spanning the ZIKV polyprotein 1049 
Allele C pr M E NS1 NS2A NS2B NS3 NS4A 2K NS4B NS5 Total 
HLA class II 25 18 15 100 70 46 26 123 25 5 50 180 683 
  1050 
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Table 3: Sequence homology between ZIKV and DENV .  Homology analysis 1051 
between BeH818995 ZIKV isolate (GenBank accession no. AMA12084.1) and DENV1, 2, 3, 4 1052 
consensus sequences obtained as previously reported(44, 45).  1053 
a) Average of structural and non-structural proteins based on average of the different 1054 
homology values in the four DENV serotypes for each protein.  1055 
b) Average conservation on a per-residue based of structural and non-structural proteins 1056 
accounting for size. 1057 
  1058 
 
ZIKV 
Serotype Polyprotein C prM E NS1 NS2A NS2B NS3 NS4A+2k NS4B NS5 
DENV1 55% 50% 43% 57% 54% 30% 35% 66% 43% 51% 67% 
DENV2 56% 41% 41% 55% 54% 27% 41% 67% 52% 53% 67% 
DENV3 57% 50% 42% 58% 55% 29% 38% 67% 39% 52% 67% 
DENV4 57% 49% 47% 56% 54% 34% 41% 67% 44% 49% 68% 
Average 56% 47% 43% 58% 55% 31% 39% 67% 44% 51% 67% 
Average of structural proteins a) 49% Average of non-structural proteins a) 51% 
Average of structural proteins accounting for 
size  b) 
51% 
Average of non-structural proteins accounting for 
size  b) 
58% 
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Table 4:  Monoclonal antibodies used in this study. 1059 
 1060 
  1061 
Target Color Clone Company 
CD3 AlexaFluor700 UCHT1 eBioscience 
CD4 APC-eFluor780 RPA-T4 eBioscience 
CD8 BV650 RPA-T8 Biolegend 
CD14 V500 M5E2 BD Biosciences 
CD19 V500 HIB19 BD Biosciences 
Live/Dead ef506 
 
eBioscience 
IFNγ FITC 4S.B3 eBioscience 
CD45RA eFlour450 HI100 eBioscience 
CCR7 PerCPCy5.5 G043H7 Biolegend 
TNFα PE-Cy7 Mab11 EBioscience 
PD1 PE-CF594 EH12.1 BD Biosciences 
Granzyme B PE GB11 EBioscience 
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Table 5: Donors tested in each category 1062 
# of samples ZIKV status a) DENV status c) Country of origin 
18 Acute Pos. Brazil /Mexico 
17 Acute Neg. Nicaragua/Mexico 
33 Convalescent Pos. Brazil/US travelers/ blood bank donors 
30 Convalescent Neg. US travelers/ blood bank donors 
20 Neg. b) Pos. Nicaragua/ Sri Lanka 
20 Neg. Neg. US 
a) Infection with ZIKV was confirmed by RT-PCR 1063 
b) ZIKV-neg. samples were collected before the onset of the ZIKV epidemic 1064 
c) Previous exposure to DENV was determined by the presence of detectable DENV-1065 
specific IgG titers. 1066 
1067 
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Table 6. Testing of DENV corresponding peptides for ZIKV NS52868-2876 NS31725-1068 
1734, and E485-493 peptides.  1069 
 1070 
Donor 
DENV 
Status 
ZIKV 
Status 
Protein Source 
Peptide 
Sequence 
SFC/10
6 a)
 
GN0101 pos neg NS52868-2876 
ZIKV TPYGQQRVF 353 ± 240
 
 
DENV1-4 TPFGQQRVF 366 ± 120 
  
   
GS0157 pos neg NS31725-1734 
ZIKV APTRVVAAEM 330 ± 75
 
 
DENV1  APTRVVASEM 219 ± 64 
2894 neg pos  E485-493 
ZIKV GLDFSDLYY 287 ± 50 
DENV1-3 GLDFNEMVL 0 
DENV4 GIDFNEMVL 0 
a)Average and Standard deviation of net responses from 6-9 independent wells for donors GN0101 and GS0157, 1071 
and 3 independent wells for donor 2894. 1072 
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